Oncostatin M modulates fibroblast function via signal transducers and activators of transcription proteins-3

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 4, 2013, Pages 582-591

  Nagahama, Kumi Yoneda ^a   Togo, Shinsaku ^a   Holz, Olaf ^b   Magnussen, Helgo ^c   Liu, Xiangde ^d   Seyama, Kuniaki ^a   Takahashi, Kazuhisa ^a   Rennard, Stephen I ^d  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^c KRANKENHAUS GROSSHANSDORF   (Germany)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Asthma; Chemotaxis; Contractility; Fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN GEL; FIBRONECTIN; INTERLEUKIN 13; INTERLEUKIN 4; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOSTATIN M; PROSTAGLANDIN E2; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

AIRWAY REMODELING; ARTICLE; ASTHMA; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; FETUS; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LUNG FIBROBLAST; LUNG FIBROSIS; MUSCLE FIBER CONTRACTION; MYOFIBROBLAST; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ACTINS; CELLS, CULTURED; CHEMOTAXIS; COLLAGEN; FIBROBLASTS; FIBRONECTINS; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; JANUS KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOSTATIN M; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84886471855     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0460OC     Document Type: Article

References (49)

1. Al-Muhsen S, Johnson JR, Hamid Q. Remodeling in asthma. J Allergy Clin Immunol 2011;128:451-462.
2. Brewster CE, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR. Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1990;3:507-511.
3. Simpson JL, Baines KJ, Boyle MJ, Scott RJ, Gibson PG. Oncostatin M (OSM) is increased in asthma with incompletely reversible airflow obstruction. Exp Lung Res 2009;35:781-794.
4. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009;136:1364-1370.
5. Heinrich PC, Behrmann I, M'ller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/JAK/STAT pathway. Biochem J 1998;334:297-314.
6. O'Hara KA, Kedda MA, Thompson PJ, Knight DA. Oncostatin M: an interleukin-6-like cytokine relevant to airway remodelling and the pathogenesis of asthma. Clin Exp Allergy 2003;33:1026-1032.
7. Scaffidi AK, Mutsaers SE, Moodley YP, McAnulty RJ, Laurent GJ, Thompson PJ, Knight DA. Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts. Br J Pharmacol 2002;136:793-801.
8. Mozaffarian A, Brewer AW, Trueblood ES, Luzina IG, Todd NW, Atamas SP, Arnett HA. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol 2008;181:7243-7253.
9. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999;54:825-857.
10. Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 2010;298:L715-L731.
11. Fritz DK, Kerr C, Botelho F, Stampfli M, Richards CD. Oncostatin M (OSM) primes IL-13-and IL-4-induced eotaxin responses in fibroblasts: regulation of the Type-II IL-4 receptor chains IL-4Ralpha and IL-13Ralpha1. Exp Cell Res 2009;315:3486-3499.
12. Faffe DS, Flynt L, Mellema M, Moore PE, Silverman ES, Subramaniam V, Jones MR, Mizgerd JP, Whitehead T, Imrich A, et al. Oncostatin M causes eotaxin-1 release from airway smooth muscle: synergy with IL-4 and IL-13. J Allergy Clin Immunol 2005;115:514-520.
13. Holz O, Z'hlke I, Jaksztat E, M'ller KC, Welker L, Nakashima M, Diemel KD, Branscheid D, Magnussen H, J'rres RA. Lung fibroblasts from patients with emphysema show a reduced proliferation rate in culture. Eur Respir J 2004;24:575-579.
14. Boyden S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 1962;115:453-466.
15. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci USA 1979;76:1274-1278.
16. Kamio K, Liu X, Sugiura H, Togo S, Kobayashi T, Kawasaki S, Wang X, Mao L, Ahn Y, Hogaboam C, et al. Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the cAMP-PKA pathway. Am J Respir Cell Mol Biol 2007;37:113-120.
17. Brown TJ, Rowe JM, Liu JW, Shoyab M. Regulation of IL-6 expression by oncostatin M. J Immunol 1991;147:2175-2180.
18. Roth M, Nauck M, Tamm M, Perruchoud AP, Ziesche R, Block LH. Intracellular interleukin 6 mediates platelet-derived growth factor-induced proliferation of nontransformed cells. Proc Natl Acad Sci USA 1995;92:1312-1316.
19. Finesmith TH, Broadley KN, Davidson JM. Fibroblasts from wounds of different stages of repair vary in their ability to contract a collagen gel in response to growth factors. J Cell Physiol 1990;144:99-107.
20. Cazes E, Giron-Michel J, Baouz S, Doucet C, Cagnoni F, Oddera S, K'rner M, Dasic G, Testi R, Azzarone B, et al. Novel antiinflammatory effects of the inhaled corticosteroid fluticasone propionate during lung myofibroblastic differentiation. J Immunol 2001;167:5329-5337.
21. Liu X, Kohyama T, Wang H, Zhu YK, Wen FQ, Kim HJ, Romberger DJ, Rennard SI. Th2 cytokine regulation of Type I collagen gel contraction mediated by human lung mesenchymal cells. Am J Physiol Lung Cell Mol Physiol 2002;282:L1049- L1056.
22. Langdon C, Kerr C, Tong L, Richards CD. Oncostatin M regulates eotaxin expression in fibroblasts and eosinophilic inflammation in C57BL/6 mice. J Immunol 2003;170:548-555.
23. Fritz DK, Kerr C, Tong L, Smyth D, Richards CD. Oncostatin-M up-regulates VCAM-1 and synergizes with IL-4 in eotaxin expression: involvement of STAT6. J Immunol 2006;176:4352-4360.
24. Guo F, Carter DE, Mukhopadhyay A, Leask A. Gingival fibroblasts display reduced adhesion and spreading on extracellular matrix: a possible basis for scarless tissue repair? PLoS ONE 2011;6:e27097.
25. Yoshizuka N, Chen RM, Xu Z, Liao R, Hong L, Hu WY, Yu G, Han J, Chen L, Sun P. A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis. Mol Cell Biol 2012;32:606-618.
26. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 2002;115:3193-3206.
27. Hsu HJ, Lee CF, Locke A, Vanderzyl SQ, Kaunas R. Stretch-induced stress fiber remodeling and the activations of JNK and ERK depend on mechanical strain rate, but not FAK. PLoS ONE 2010;5:e12470.
28. Chiquet M, Renedo AS, Huber F, Fl'ck M. How do fibroblasts translate mechanical signals into changes in extracellular matrix production? Matrix Biol 2003;22:73-80.
29. Ihn H, Tamaki K. Oncostatin Mstimulates the growth of dermal fibroblasts via a mitogen-activated protein kinase-dependent pathway. J Immunol 2000;165:2149-2155.
30. Levy MT, Trojanowska M, Reuben A. Oncostatin M, a cytokine upregulated in human cirrhosis, increases collagen production by human hepatic stellate cells. J Hepatol 2000;32:218-226.
31. de Hooge AS, van de Loo FA, Bennink MB, de Jong DS, Arntz OJ, Lubberts E, Richards CD, van den Berg WB. Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. Am J Pathol 2002;160:1733-1743.
32. Kotaru C, Schoonover KJ, Trudeau JB, Huynh ML, Zhou X, Hu H, Wenzel SE. Regional fibroblast heterogeneity in the lung: implications for remodeling. Am J Respir Crit Care Med 2006;173:1208-1215.
33. Nihlberg K, Andersson-Sj'land A, Tufvesson E, Erjef'lt JS, Bjermer L, Westergren-Thorsson G. Altered matrix production in the distal airways of individuals with asthma. Thorax 2010;65:670-676.
34. Pechkovsky DV, Pr'le CM, Wong J, Hogaboam CM, McAnulty RJ, Laurent GJ, Zhang SS, Selman M, Mutsaers SE, Knight DA. STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF. Am J Pathol 2012;180:1398-1412.
35. Sugiura H, Liu X, Duan F, Kawasaki S, Togo S, Kamio K, Wang XQ, Mao L, Ahn Y, Ertl RF, et al. Cultured lung fibroblasts from ovalbumin-challenged 'asthmatic' mice differ functionally from normal. Am J Respir Cell Mol Biol 2007;37:424-430.
36. Migita K, Komori A, Torigoshi T, Maeda Y, Izumi Y, Jiuchi Y, Miyashita T, Nakamura M, Motokawa S, Ishibashi H. CP690550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes. Arthritis Res Ther 2011;13:R72.
37. Smyth DC, Kerr C, Li Y, Tang D, Richards CD. Oncostatin M induction of eotaxin-1 expression requires the convergence of PI39K and ERK1/ 2 MAPK signal transduction pathways. Cell Signal 2008;20:1142-1150.
38. Rennard SI, Hunninghake GW, Bitterman PB, Crystal RG. Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. Proc Natl Acad Sci USA 1981;78:7147-7151.
39. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-1358.
40. Bogatkevich GS, Tourkina E, Abrams CS, Harley RA, Silver RM, Ludwicka-Bradley A. Contractile activity and smooth muscle alpha-actin organization in thrombin-induced human lung myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2003;285:L334-L343.
41. Sanchez C, Deberg MA, Burton S, Devel P, Reginster JY, Henrotin YE. Differential regulation of chondrocyte metabolism by oncostatin M and interleukin-6. Osteoarthritis Cartilage 2004;12:801-810.
42. O'Donoghue RJ, Knight DA, Richards CD, Prele CM, Lau HL, Jarnicki AG, Jones J, Bozinovski S, Vlahos R, Thiem S, et al. Genetic partitioning of interleukin-6 signalling in mice dissociates STAT3 from Smad3-mediated lung fibrosis. EMBO Mol Med 2012;4:939-951.
43. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
44. Ying S, Durham SR, Corrigan CJ, Hamid Q, Kay AB. Phenotype of cells expressing mRNA for Th2-type (interleukin 4 and interleukin 5) and Th1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995;12:477-487.
45. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001;194:809-821.
46. Kohyama T, Ertl RF, Valenti V, Spurzem J, Kawamoto M, Nakamura Y, Veys T, Allegra L, Romberger D, Rennard SI. Prostaglandin E(2) inhibits fibroblast chemotaxis. Am J Physiol Lung Cell Mol Physiol 2001;281:L1257-L1263.
47. Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ, Moore BB. Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 2003;29:537-544.
48. Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM, Peters-Golden M. Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol Lung Cell Mol Physiol 2007;292: L405-L413.
49. Elsdale T, Bard J. Collagen substrata for studies on behavior. J Cell Biol 1972;54:626-637.